We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Masspec Pen Evaluated for Rapid Diagnosis of Cancer

By LabMedica International staff writers
Posted on 20 Jun 2019
Ovarian cancer is a highly lethal disease and the fifth leading cause of all cancer-related deaths in women. More...
Accurate diagnosis and stratification of ovarian cancer is important to develop personalized treatment approaches.

Current methods for intraoperative tissue evaluation can be time intensive and subjective. A handheld and biocompatible device coupled to a mass spectrometer, has been developed, which uses a discrete water droplet for molecular extraction and rapid tissue diagnosis.

Scientists at The University of Texas at Austin (Austin, TX, USA) used the devise called the MasSpec Pen to analyze its performance on 192 ovarian, fallopian tube, and peritoneum tissue samples. The analyzed area of the tissue was demarcated and registered through optical images. Demarcated tissue or a parallel piece was frozen and sectioned at 10–16 μm using a CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham MA, USA), stained by standard hematoxylin and eosin procedure, and evaluated by expert pathologists to confirm diagnosis of the analyzed area. Performance using an Orbitrap and a linear ion trap mass spectrometer was tested. Of note, the final diagnoses were performed after MasSpec Pen analyses. Only 164 samples with clear diagnosis were used for statistical analysis.

The team reported that a high performance for 131 high-grade serous carcinoma (clinical sensitivity, 96.7%; specificity, 95.7%) and 138 overall cancer (clinical sensitivity, 94.0%; specificity, 94.4%) diagnoses was achieved using Orbitrap data. Discrimination between cancer and fallopian tube or peritoneum tissues was also achieved with accuracies of 92.6% and 87.9%, respectively, and 100% clinical specificity for both. Using ion trap data, excellent results for high-grade serous cancer versus normal ovarian differentiation were achieved.

The authors concluded that the MasSpec Pen, together with machine learning, provides robust molecular models for ovarian serous cancer prediction and thus has potential for clinical use for rapid and accurate ovarian cancer diagnosis. The study was published in the May 2019 issue of the journal Clinical Chemistry.

Related Links:
The University of Texas at Austin
Thermo Fisher Scientific



New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.